367 related articles for article (PubMed ID: 7881104)
1. Transcriptional regulation of multidrug resistance in breast cancer.
Glazer RI; Rohlff C
Breast Cancer Res Treat; 1994; 31(2-3):263-71. PubMed ID: 7881104
[TBL] [Abstract][Full Text] [Related]
2. Regulation of multidrug resistance through the cAMP and EGF signalling pathways.
Rohlff C; Glazer RI
Cell Signal; 1995 Jul; 7(5):431-43. PubMed ID: 8562304
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.
Scala S; Budillon A; Zhan Z; Cho-Chung YS; Jefferson J; Tsokos M; Bates SE
J Clin Invest; 1995 Aug; 96(2):1026-34. PubMed ID: 7543490
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
5. Lack of modulation of MDR1 gene expression by dominant inhibition of cAMP-dependent protein kinase in doxorubicin-resistant MCF-7 breast cancer cells.
Parissenti AM; Gannon BR; Villeneuve DJ; Kirwan-rhude AF; Chadderton A; Glück S
Int J Cancer; 1999 Sep; 82(6):893-900. PubMed ID: 10446459
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1.
Rohlff C; Glazer RI
Int J Oncol; 1998 Feb; 12(2):383-6. PubMed ID: 9458366
[TBL] [Abstract][Full Text] [Related]
7. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
8. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
9. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
10. Constitutive levels of cAMP-dependent protein kinase activity determine sensitivity of human multidrug-resistant leukaemic cell lines to growth inhibition and apoptosis by forskolin and tumour necrosis factor alpha.
Yin Y; Allen PD; Jia L; MacEy MG; Kelsey SM; Newland AC
Br J Haematol; 2000 Mar; 108(3):565-73. PubMed ID: 10759715
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas.
Lacave R; Coulet F; Ricci S; Touboul E; Flahault A; Rateau JG; Cesari D; Lefranc JP; Bernaudin JF
Br J Cancer; 1998 Mar; 77(5):694-702. PubMed ID: 9514046
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.
Trock BJ; Leonessa F; Clarke R
J Natl Cancer Inst; 1997 Jul; 89(13):917-31. PubMed ID: 9214671
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
14. Determining MDR1/P-glycoprotein expression in breast cancer.
Faneyte IF; Kristel PM; van de Vijver MJ
Int J Cancer; 2001 Jul; 93(1):114-22. PubMed ID: 11391630
[TBL] [Abstract][Full Text] [Related]
15. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs.
Jin W; Liu Y; Xu SG; Yin WJ; Li JJ; Yang JM; Shao ZM
Breast Cancer Res Treat; 2010 Nov; 124(1):39-48. PubMed ID: 20037778
[TBL] [Abstract][Full Text] [Related]
16. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta.
Gill PK; Gescher A; Gant TW
Eur J Biochem; 2001 Aug; 268(15):4151-7. PubMed ID: 11488907
[TBL] [Abstract][Full Text] [Related]
17. Role of gene amplification in drug resistance.
Schoenlein PV
Cancer Treat Res; 1994; 73():167-200. PubMed ID: 7710905
[No Abstract] [Full Text] [Related]
18. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies.
Kuwano M; Uchiumi T; Hayakawa H; Ono M; Wada M; Izumi H; Kohno K
Cancer Sci; 2003 Jan; 94(1):9-14. PubMed ID: 12708467
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
